Uploaded August 2026 | Updated September 2026, 2 weeks ago
"Tissue Culture, Clonal Integrity & Regeneration Innovation" panel discussion at CannMed 2026, covering somaclonal variation, clonal identity verification, and clean-stock propagation.
As cannabis cultivation scales, tissue culture is no longer just a sanitation tool, it is a foundational technology for genetic preservation, IP protection, and yield consistency. This panel examines the biological, technical, and governance frameworks required to deploy tissue culture at industrial scale without sacrificing clonal integrity.
Panelists outline how modern tissue culture programs can be scientifically validated, economically justified, and legally defensible, including mechanisms driving somaclonal variation and how to mitigate them, hormonal and genetic controls governing regeneration fidelity, quality-control frameworks for clonal identity verification, scaling clean-stock programs without runaway cost or contamination risk, and aligning tissue culture workflows with IP strategy, breeding pipelines, and enterprise operations.
Panelists:
Michael Catalano (Moderator), Head of International Sales & Genomic Services, Medicinal Genomics
Michael Deyholos, PhD, Professor, University of British Columbia
Lasse Schulze, PhD, Senior Director, Flower Product Development and Agronomics, Cronos Group
William Graham, Founder and President, Microclone Tissue Culture
Walter Viss, CTO, Conception Nurseries
This panel was part of the CannMed Cultivation Workshop, a program focused on the science of sustainable cannabis production.
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
"Tissue Culture, Clonal Integrity & Regeneration Innovation" panel discussion at CannMed 2026, covering somaclonal variation, clonal identity verification, and clean-stock propagation.
As cannabis cultivation scales, tissue culture is no longer just a sanitation tool, it is a foundational technology for genetic preservation, IP protection, and yield consistency. This panel examines the biological, technical, and governance frameworks required to deploy tissue culture at industrial scale without sacrificing clonal integrity.
Panelists outline how modern tissue culture programs can be scientifically validated, economically justified, and legally defensible, including mechanisms driving somaclonal variation and how to mitigate them, hormonal and genetic controls governing regeneration fidelity, quality-control frameworks for clonal identity verification, scaling clean-stock programs without runaway cost or contamination risk, and aligning tissue culture workflows with IP strategy, breeding pipelines, and enterprise operations.
Panelists:
Michael Catalano (Moderator), Head of International Sales & Genomic Services, Medicinal Genomics
Michael Deyholos, PhD, Professor, University of British Columbia
Lasse Schulze, PhD, Senior Director, Flower Product Development and Agronomics, Cronos Group
William Graham, Founder and President, Microclone Tissue Culture
Walter Viss, CTO, Conception Nurseries
This panel was part of the CannMed Cultivation Workshop, a program focused on the science of sustainable cannabis production.
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
